Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update reports a study evaluating MW02 for wet age-related macular degeneration across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• MW02

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Wet Age-related Macular Degeneration | Phase 2, Phase 3 | Status: UNKNOWN